Enanta Pharmaceuticals (ENTA) Cash from Operations Growth (5y) (2017 - 2026)
Enanta Pharmaceuticals (ENTA) Cash from Operations Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.34% |
| Dec 31, 2025 | 4.71% |
| Sep 30, 2025 | 15.94% |
| Jun 30, 2025 | 42.62% |
| Mar 31, 2025 | -23.89% |
| Dec 31, 2024 | -27.42% |
| Sep 30, 2024 | -26.33% |
| Jun 30, 2024 | -50.93% |
| Mar 31, 2024 | -24.16% |
| Dec 31, 2023 | -23.09% |
| Sep 30, 2023 | -22.53% |
| Jun 30, 2023 | -58.29% |
| Mar 31, 2023 | -12.71% |
| Dec 31, 2022 | -58.75% |
| Sep 30, 2022 | -17.83% |
| Jun 30, 2022 | -43.91% |
| Mar 31, 2022 | -54.44% |
| Dec 31, 2021 | -44.13% |
| Sep 30, 2021 | -58.13% |
| Jun 30, 2021 | -69.45% |